Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

PHASE3CompletedINTERVENTIONAL
Enrollment

654

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 15, 2017

Study Completion Date

May 15, 2017

Conditions
Atopic Dermatitis
Interventions
DRUG

Pimecrolimus Cream, 1%

DRUG

Placebo Cream

DRUG

Pimecrolimus Cream, 1%

Trial Locations (27)

19103

Resarch Facility 8, Philadelphia

23220

Research Facility 15, Richmond

27262

Research Facility 2, High Point

28277

Research Facility 24, Charlotte

33014

Research Facility 1, Miami Lakes

33027

Research Facility 9, Miramar

33144

Research Facility 5, Miami

33146

Research Facility 4, Coral Gables

33172

Research Facility 33, Sweetwater

33175

Research Facility 10, Miami

33437

Research Facility 6, Boynton Beach

40241

Research Facility 32, Louisville

64506

Research Facility 7, Saint Joseph

66215

Research Facility 28, Overland Park

68114

Research Facility 19, Omaha

70115

Research Facility 13, New Orleans

77479

Research Facility 17, Sugar Land

77845

Research Facility 16, College Station

78660

Research Facility 31, Pflugerville

78759

Research Facility 20, Austin

83704

Research Facility 23, Boise

84088

Research Facility 22, West Jordan

87106

Research Facility 29, Albuquerque

99202

Research Facility 26, Spokane

02919

Research Facility 18, Johnston

Unknown

Research Facility 11, Santo Domingo

Research Facility 12, San Pedro Sula

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

DPT Laboratories, Ltd.

INDUSTRY

lead

Mylan Inc.

INDUSTRY

NCT03107611 - Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis | Biotech Hunter | Biotech Hunter